Koers Lexicon Pharmaceuticals, Inc. Nasdaq
Aandelen
US5288721047
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 25,81 mln. 24,14 mln. | Omzet 2025 * | 77,52 mln. 72,5 mln. | Marktkapitalisatie | 389 mln. 364 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -199 mln. -186 mln. | Nettowinst (verlies) 2025 * | -193 mln. -181 mln. | EV/omzet 2024 * | 15,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 5,02 x |
K/w-verhouding 2024 * |
-2,22
x | K/w-verhouding 2025 * |
-2,49
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,99% |
Recentste transcriptie over Lexicon Pharmaceuticals, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 07-07-14 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 01-01-99 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 02-08-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-02-01 |
Ray Debbane
CHM | Chairman | 69 | 01-08-07 |
Director/Board Member | 65 | 28-08-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |